Iterion Therapeutics
Biotechnology, 2450 Holcombe BLVD, Houston, Texas, 77021, United States, 11-50 Employees
Phone Number: 83********
Who is ITERION THERAPEUTICS
Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent...
Read More
-
Headquarters: 2450 Holcombe BLVD, Houston, Texas, 77021, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2899
Does something look wrong? Fix it. | View contact records from ITERION THERAPEUTICS
Iterion Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Iterion Therapeutics
Answer: Iterion Therapeutics's headquarters are located at 2450 Holcombe BLVD, Houston, Texas, 77021, United States
Answer: Iterion Therapeutics's phone number is 83********
Answer: Iterion Therapeutics's official website is https://iteriontherapeutics.com
Answer: Iterion Therapeutics's revenue is $1 Million to $5 Million
Answer: Iterion Therapeutics's SIC: 2899
Answer: Iterion Therapeutics has 11-50 employees
Answer: Iterion Therapeutics is in Biotechnology
Answer: Iterion Therapeutics contact info: Phone number: 83******** Website: https://iteriontherapeutics.com
Answer: Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month